Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4DMedical Ltd ( (AU:4DX) ) just unveiled an announcement.
4DMedical Limited has announced its Annual General Meeting scheduled for 30 October 2025, where shareholders will review the company’s FY25 performance and vote on various business items, including the re-election of directors and the issuance of securities. This meeting is a significant event for stakeholders as it will provide insights into the company’s strategic direction and financial health, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global medical technology company specializing in advanced respiratory imaging technology. The company offers innovative solutions such as the FDA-cleared XV Lung Ventilation Analysis Software and the CT:VQ solution, which enhance the detection, diagnosis, and monitoring of lung diseases. Their products are delivered through a Software-as-a-Service model, integrating seamlessly into existing hospital systems to improve physician productivity and patient care. With the acquisition of Imbio in 2023, 4DMedical has incorporated advanced AI capabilities to further push the boundaries of medical imaging.
Average Trading Volume: 6,385,744
Technical Sentiment Signal: Buy
Current Market Cap: A$910.2M
For detailed information about 4DX stock, go to TipRanks’ Stock Analysis page.